A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE)

ConclusionOur case supports the efficacy of immunotherapies for NORSE even though it does not manifest definite evidence for autoimmune background. Clinicians should consider these immunotherapies for NORSE as early as possible, because this condition is associated with high mortality and morbidity owing to prolonged seizure activity and long-term intensive care including general anesthesia and mechanical ventilation.
Source: Journal of Intensive Care - Category: Intensive Care Source Type: research